NCT07094763View on ClinicalTrials.gov

Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset

NANot yet recruitingINTERVENTIONAL
Enrollment

406

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

October 30, 2027

Study Completion Date

December 30, 2027

Conditions
Acute Ischemic Stroke
Interventions
DRUG

TNK plus standard medical treatment

Patients in the TNK treatment group will receive TNK intravenous thrombolysis and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg.

DRUG

standard medical management

standard medical management

Trial Locations (1)

Unknown

The First Affiliated Hospital of the University of Science and Technology of China, Hefei

All Listed Sponsors
lead

The First Affiliated Hospital of University of Science and Technology of China

OTHER

NCT07094763 - Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset | Biotech Hunter | Biotech Hunter